KalVista Releases Data on Pediatric Hereditary Angioedema Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2026
0mins
KalVista Pharmaceuticals announced new data highlighting the burden of injectable on-demand treatment in children aged 2-11 with hereditary angioedema presented at ISPOR 2026 and the Eastern Allergy Conference. On-Demand Treatments for Hereditary Angioedema and Healthcare Resource Utilization in Pediatric Patients: A US Claims Database Analysis: Real-world claims data showed that while about two thirds of children aged 2-11 were prescribed IV pdC1INH-the only FDA-approved on-demand HAE treatment for this population-the majority of treatments utilized were off-label, suggesting families and providers may be seeking less invasive treatment options. Although the mean on-demand dosing rate was 0.43 per patient per month, the rate for pdC1INH was far less than that of icatibant. Burden of Injectable On-Demand Treatment for Hereditary Angioedema Attacks in Children: A caregiver survey found that nearly half of children did not receive on-demand treatment for their most recent HAE attack. Among children who did treat their last attack, 93.7% experienced anxiety about using injectable on-demand treatment, with 68.8% reporting extreme anxiety. Caregiver Burden Associated with Injectable On-Demand Treatment of Hereditary Angioedema Attacks in Children: The same caregiver survey found that during their child's last HAE attack, 43% occurred outside the home and 37% occurred while they were not with their child. 63% of caregivers had difficulty administering treatment and 31% took their child to a hospital or emergency center for treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.000
Low
29.00
Averages
34.38
High
39.00
Current: 27.000
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Merger Transaction Investigation: Halper Sadeh LLC is investigating the merger between Rallybio Corporation and Avenzo Therapeutics, Inc., with Rallybio shareholders expected to own approximately 2.8% of the combined entity post-transaction, which may impact shareholder rights and future returns.
- Cash Acquisition Analysis: KalVista Pharmaceuticals, Inc. is being sold to Chiesi Group for $27.00 per share, and Halper Sadeh LLC is urging shareholders to be aware of their legal rights and options to ensure fair transaction terms.
- Shareholder Rights Protection: InMed Pharmaceuticals, Inc.'s merger with Mentari Therapeutics, Inc. is projected to result in InMed shareholders owning about 1.51% of the new company, prompting Halper Sadeh LLC to encourage shareholders to understand their rights for better terms in the deal.
- Cash Transaction Impact: Taylor Morrison Home Corporation is being sold to Berkshire Hathaway Inc. for $72.50 per share, with Halper Sadeh LLC representing shareholders in seeking increased consideration and additional disclosures to protect investor interests.
See More
KalVista Executive Sells Stock Options Amid Buyout Offer
- Transaction Overview: Christopher Yea exercised 33,800 options and sold them for approximately $905,000 on May 27, 2026, reducing his direct holdings to 229,918 shares, indicating a potential lack of confidence in the company's future prospects.
- Buyout Proposal Impact: Yea sold shares at $26.78 each, while Chiesi Group's pending buyout offer stands at $27 per share, suggesting that Yea's decision to sell may have been hasty, potentially missing out on greater returns.
- Ekterly Market Potential: KalVista's Ekterly, launched in July 2025, achieved $49 million in sales last year, and if FDA approval extends its use to children aged 2 to 11, it could significantly boost market demand and address unmet medical needs.
- Financial Performance Warning: Despite Ekterly's strong initial performance, KalVista reported a loss of $109.5 million for the eight months ending December 31, 2025, highlighting challenges in profitability that may affect investor confidence moving forward.
See More
KalVista Executive Sells Stock Options Amid Buyout Offer
- Transaction Overview: Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, exercised 33,800 stock options and immediately sold them for approximately $905,000, indicating a short-term liquidity need for his shares.
- Holding Changes: Following this transaction, Yea holds 229,918 shares valued at about $6.16 million, and despite a 28.84% reduction in direct holdings over the past year, his selling behavior does not significantly increase long-term holding risks.
- Acquisition Context: Yea sold shares at $26.78 each while Chiesi Group has made a buyout offer at $27 per share, reflecting the market's assessment of KalVista's potential value amid acquisition talks.
- Product Market Outlook: KalVista's Ekterly drug, launched in July 2025, achieved $49 million in sales last year, and if approved for use in children aged 2 to 11 by the FDA, it is expected to drive further sales growth.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating KalVista Pharmaceuticals (NASDAQ:KALV) for potential violations of federal securities laws related to its sale to Chiesi Group for $27.00 per share in cash, indicating possible breaches of fiduciary duties to shareholders.
- Shareholder Rights: The firm encourages KalVista shareholders to reach out to discuss their rights and options, highlighting the potential financial disadvantages they may face compared to ordinary shareholders in the proposed transaction.
- Other Companies Under Scrutiny: The investigation also includes Global Business Travel Group (NYSE:GBTG) selling for $9.50 per share to Long Lake Management, Modiv Industrial (NYSE:MDV) merging with Global Net Lease, and Catalyst Pharmaceuticals (NASDAQ:CPRX) selling for $31.50 per share to Angelini Pharma S.p.A.
- Legal Support Offered: Halper Sadeh LLC aims to seek increased consideration, additional disclosures, and other relief on behalf of shareholders, demonstrating a commitment to protecting shareholder interests and rights throughout these transactions.
See More
Monteverde Law Firm Investigates Multiple M&A Transactions
- Shareholder Rights Investigation: Monteverde & Associates is investigating the transaction between Modiv Industrial, Inc. and Global Net Lease, Inc., where Modiv shareholders are expected to own approximately 11% of the combined entity, potentially impacting long-term shareholder returns.
- Cash Return Commitment: Shareholders of Global Business Travel Group, Inc. are expected to receive $9.50 per share in cash, which may provide immediate liquidity and enhance investor confidence in the transaction.
- Acquisition Price Transparency: KalVista Pharmaceuticals, Inc. shareholders are anticipated to receive $27.00 per share in cash, reflecting market recognition of the company and potentially attracting more investor interest.
- Merger Voting Arrangement: The merger plan between Legato Meger Corp. III and Einride AB is set for a shareholder vote on June 4, 2026, where shareholders will exchange each Legato ordinary share for Einride common stock, potentially affecting shareholder structure and future earnings.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) for its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, raising concerns about potential shareholder rights violations and encouraging shareholders to explore their options.
- Acquisition Terms: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is being sold to Chiesi Group for $27.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration to ensure fair compensation for shareholders.
- Transaction Options: Thermon Group Holdings, Inc. (NYSE:THR) is proposed to be sold to CECO Environmental Corp., offering shareholders a choice between cash and stock combinations or $63.89 per share in cash, with Halper Sadeh LLC advocating for better terms on behalf of shareholders.
- Legal Support: Lisata Therapeutics, Inc. (NASDAQ:LSTA) is selling to Kuva Labs, Inc. for $4.00 per share, and Halper Sadeh LLC provides no-cost legal consultations to help shareholders understand their rights and options, ensuring their legal interests are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Merger Transaction Investigation: Halper Sadeh LLC is investigating the merger between Rallybio Corporation and Avenzo Therapeutics, Inc., with Rallybio shareholders expected to own approximately 2.8% of the combined entity post-transaction, which may impact shareholder rights and future returns.
- Cash Acquisition Analysis: KalVista Pharmaceuticals, Inc. is being sold to Chiesi Group for $27.00 per share, and Halper Sadeh LLC is urging shareholders to be aware of their legal rights and options to ensure fair transaction terms.
- Shareholder Rights Protection: InMed Pharmaceuticals, Inc.'s merger with Mentari Therapeutics, Inc. is projected to result in InMed shareholders owning about 1.51% of the new company, prompting Halper Sadeh LLC to encourage shareholders to understand their rights for better terms in the deal.
- Cash Transaction Impact: Taylor Morrison Home Corporation is being sold to Berkshire Hathaway Inc. for $72.50 per share, with Halper Sadeh LLC representing shareholders in seeking increased consideration and additional disclosures to protect investor interests.
See More
KalVista Executive Sells Stock Options Amid Buyout Offer
- Transaction Overview: Christopher Yea exercised 33,800 options and sold them for approximately $905,000 on May 27, 2026, reducing his direct holdings to 229,918 shares, indicating a potential lack of confidence in the company's future prospects.
- Buyout Proposal Impact: Yea sold shares at $26.78 each, while Chiesi Group's pending buyout offer stands at $27 per share, suggesting that Yea's decision to sell may have been hasty, potentially missing out on greater returns.
- Ekterly Market Potential: KalVista's Ekterly, launched in July 2025, achieved $49 million in sales last year, and if FDA approval extends its use to children aged 2 to 11, it could significantly boost market demand and address unmet medical needs.
- Financial Performance Warning: Despite Ekterly's strong initial performance, KalVista reported a loss of $109.5 million for the eight months ending December 31, 2025, highlighting challenges in profitability that may affect investor confidence moving forward.
See More
KalVista Executive Sells Stock Options Amid Buyout Offer
- Transaction Overview: Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, exercised 33,800 stock options and immediately sold them for approximately $905,000, indicating a short-term liquidity need for his shares.
- Holding Changes: Following this transaction, Yea holds 229,918 shares valued at about $6.16 million, and despite a 28.84% reduction in direct holdings over the past year, his selling behavior does not significantly increase long-term holding risks.
- Acquisition Context: Yea sold shares at $26.78 each while Chiesi Group has made a buyout offer at $27 per share, reflecting the market's assessment of KalVista's potential value amid acquisition talks.
- Product Market Outlook: KalVista's Ekterly drug, launched in July 2025, achieved $49 million in sales last year, and if approved for use in children aged 2 to 11 by the FDA, it is expected to drive further sales growth.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating KalVista Pharmaceuticals (NASDAQ:KALV) for potential violations of federal securities laws related to its sale to Chiesi Group for $27.00 per share in cash, indicating possible breaches of fiduciary duties to shareholders.
- Shareholder Rights: The firm encourages KalVista shareholders to reach out to discuss their rights and options, highlighting the potential financial disadvantages they may face compared to ordinary shareholders in the proposed transaction.
- Other Companies Under Scrutiny: The investigation also includes Global Business Travel Group (NYSE:GBTG) selling for $9.50 per share to Long Lake Management, Modiv Industrial (NYSE:MDV) merging with Global Net Lease, and Catalyst Pharmaceuticals (NASDAQ:CPRX) selling for $31.50 per share to Angelini Pharma S.p.A.
- Legal Support Offered: Halper Sadeh LLC aims to seek increased consideration, additional disclosures, and other relief on behalf of shareholders, demonstrating a commitment to protecting shareholder interests and rights throughout these transactions.
See More
Monteverde Law Firm Investigates Multiple M&A Transactions
- Shareholder Rights Investigation: Monteverde & Associates is investigating the transaction between Modiv Industrial, Inc. and Global Net Lease, Inc., where Modiv shareholders are expected to own approximately 11% of the combined entity, potentially impacting long-term shareholder returns.
- Cash Return Commitment: Shareholders of Global Business Travel Group, Inc. are expected to receive $9.50 per share in cash, which may provide immediate liquidity and enhance investor confidence in the transaction.
- Acquisition Price Transparency: KalVista Pharmaceuticals, Inc. shareholders are anticipated to receive $27.00 per share in cash, reflecting market recognition of the company and potentially attracting more investor interest.
- Merger Voting Arrangement: The merger plan between Legato Meger Corp. III and Einride AB is set for a shareholder vote on June 4, 2026, where shareholders will exchange each Legato ordinary share for Einride common stock, potentially affecting shareholder structure and future earnings.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) for its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, raising concerns about potential shareholder rights violations and encouraging shareholders to explore their options.
- Acquisition Terms: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is being sold to Chiesi Group for $27.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration to ensure fair compensation for shareholders.
- Transaction Options: Thermon Group Holdings, Inc. (NYSE:THR) is proposed to be sold to CECO Environmental Corp., offering shareholders a choice between cash and stock combinations or $63.89 per share in cash, with Halper Sadeh LLC advocating for better terms on behalf of shareholders.
- Legal Support: Lisata Therapeutics, Inc. (NASDAQ:LSTA) is selling to Kuva Labs, Inc. for $4.00 per share, and Halper Sadeh LLC provides no-cost legal consultations to help shareholders understand their rights and options, ensuring their legal interests are protected.
See More
